Pancreatic Cancer Research

ResearcherInha UniversityNo recent work listed

Hong Hua Yan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7521-1636; OpenAlex author ID A5100365975. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2013: 3 papers · 2014: 3 papers · 2015: none · 2016: 1 paper · 2017: 3 papers · 2018: 3 papers · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper

Papers 17

  1. Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. Co-author DOI 10.4062/biomolther.2021.145↗
  2. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape. Co-author DOI 10.1016/j.canlet.2021.03.015↗
  3. Identification of DNA methylation-driven genes and construction of a nomogram to predict overall survival in pancreatic cancer. Co-author DOI 10.1186/s12864-021-08097-w↗
  4. An Integrative Data Mining and Omics-Based Translational Model for the Identification and Validation of Oncogenic Biomarkers of Pancreatic Cancer. Co-author DOI 10.3390/cancers11020155↗
  5. A novel tropomyosin-related kinase A inhibitor, KK5101 to treat pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.03.041↗
  6. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.09.013↗
  7. Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway. Co-author DOI 10.1159/000491058↗
  8. Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer. Co-author DOI 10.1016/j.canlet.2017.03.009↗
  9. Corrigendum to "Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer" [Cancer Lett. 396 (201… Co-author DOI 10.1016/j.canlet.2017.06.019↗
  10. Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer. Co-author DOI 10.18632/oncotarget.22850↗
  11. HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. Co-author DOI 10.18632/oncotarget.12871↗
  12. Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2014.07.001↗
  13. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. Co-author DOI 10.18632/oncotarget.2363↗
  14. HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. First author DOI 10.3892/ijo.2014.2435↗
  15. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2013.01.007↗
  16. Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer. Co-author DOI 10.1016/j.canlet.2013.04.002↗
  17. SB365, Pulsatilla saponin D suppresses proliferation and induces apoptosis of pancreatic cancer cells. Co-author DOI 10.3892/or.2013.2517↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kyung Hee Jung · 16 shared papers, 2013–2022 · strength 1.04
  2. Soon‐Sun Hong · 14 shared papers, 2013–2022 · strength 0.92
  3. Mi Kwon Son · 13 shared papers, 2013–2022 · strength 0.82
  4. Zhenghuan Fang · 9 shared papers, 2014–2022 · strength 0.67
  5. Jung Hee Park · 7 shared papers, 2016–2022 · strength 0.58
  6. Yeo Wool Kang · 6 shared papers, 2017–2022 · strength 0.52
  7. Ji Eun Lee · 5 shared papers, 2017–2021 · strength 0.38
  8. Yong‐Sung Kim · 3 shared papers, 2018–2022 · strength 0.31
  9. Sungwoo Hong · 5 shared papers, 2013–2016 · strength 0.22
  10. Ye-Lim Ryu · 4 shared papers, 2013–2014 · strength 0.16
  11. Qian Zhou · 1 shared paper, 2021 · strength 0.15
  12. Guoren Deng · 1 shared paper, 2021 · strength 0.15
  13. Guanghai Dai · 1 shared paper, 2021 · strength 0.15
  14. Ji Eun Lee · 1 shared paper, 2022 · strength 0.14
  15. Chae‐Ok Yun · 2 shared papers, 2017 · strength 0.14
  16. Marufa Rumman · 2 shared papers, 2016–2018 · strength 0.13
  17. Nguyen Phuoc Long · 1 shared paper, 2019 · strength 0.08
  18. Sung Won Kwon · 1 shared paper, 2019 · strength 0.08
  19. Soon Sun Hong · 1 shared paper, 2018 · strength 0.08
  20. Soon‐Sun Hong · 1 shared paper, 2014 · strength 0.04
  21. Hee Seung Lee · 1 shared paper, 2013 · strength 0.04
  22. Ju Hyeon Seo · 1 shared paper, 2013 · strength 0.04
  23. Sun‐Mi Yun · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.